JaLCDOI 10.18926/AMO/30755
フルテキストURL fulltext.pdf
著者 Taira, Naruto| Doihara, Hiroyoshi| Oota, Tetsuya| Hara, Fumikata| Shien, Tadahiko| Takahashi, Hirotoshi| Yoshitomi, Seiji| Ishibe, Youichi| Shimizu, Nobuyoshi|
抄録 <p>Human esophageal cancers have been shown to express high levels of epidermal growth factor receptor (EGFR) and a relationship between high EGFR expression and local advance, the number of lymph node metastases, life expectancy, and sensitivity to chemo-radiotherapy has been demonstrated. We examined the use of gefitinib, an orally active EGFR-selective tyrosine kinase inhibitor, as a new strategy for treatment of esophageal carcinoma. The effects of gefitinib were evaluated in monotherapy and in combination with radiotherapy in human esophageal carcinoma cell lines. Gefitinib produced a dose-dependent inhibition of cellular proliferation in all of the 8 esophageal carcinoma cell lines examined, with IC50 values ranging from 5.7 microM to 36.9 microM. In combination, gefitinib and radiotherapy showed a synergistic effect in 2 human esophageal carcinoma cell lines and an additive effect in 5 cell lines. Western blotting demonstrated that gefitinib blocked activation of the EGFR-extracellular signal-regulated kinase (Erk) pathway and the EGFR-phosphoinositide-3 kinase (PI3K)-Akt pathway after irradiation. These results suggest that further evaluation of EGFR blockade as a treatment for esophageal cancer should be performed, and that radiotherapy combined with EGFR blockade may enhance the response of esophageal carcinoma to therapy.</p>
キーワード gefitinib esophageal cancer radiosensitivity epidermal growth factor receptor
Amo Type Article
発行日 2006-02
出版物タイトル Acta Medica Okayama
出版者 Okayama University Medical School
開始ページ 25
終了ページ 34
ISSN 0386-300X
NCID AA00508441
資料タイプ 学術雑誌論文
言語 English
論文のバージョン publisher
査読 有り
PubMed ID 16508686
Web of Sience KeyUT 000235538900003